Sputnik V Vaccine
- 15 Apr 2021
- 4 min read
Why in News
- It is now the third coronavirus vaccine to get emergency use approval, after Covishield (Serum Institute of India) and Covaxin (Bharat Biotech).
- About the Sputnik V Vaccine:
- The Sputnik V vaccine has been developed by Gamaleya National Research Institute of Epidemiology and Microbiology in Moscow.
- It uses two different viruses that cause the common cold (adenovirus) in humans.
- The adenoviruses are weakened so they cannot replicate in humans and cannot cause disease.
- They are also modified so that the vaccine delivers a code for making the coronavirus spike protein. This aims to ensure that when the real virus tries to infect the body, it can mount an immune response in the form of antibodies.
- Sputnik uses a different vector for each of the two shots in a course of vaccination. This provides immunity with a longer duration than vaccines using the same delivery mechanism for both shots.
- The two shots are given 21 days apart.
- Sputnik V is to be stored at -18°C in its liquid form. However, in its freeze-dried form, it can be stored at 2-8°C, in a conventional refrigerator without any need to invest in additional cold-chain infrastructure.
- Phase 3 trials conducted in Russia, with the results published in The Lancet, have found it has an efficacy of 91.6%.
- In India, Dr Reddy’s conducted a bridging study after which it applied for emergency use approval.
- Trial participants were given the first dose (rAd26-) followed by a booster dose (rAd5-S) 21 days later.
- Adenoviruses (ADVs) are DNA viruses ranging from 70-90 nanometre in size, which induce many illnesses in humans like cold, respiratory infection etc.
- Adenoviruses are preferred for vaccines because their DNA is double stranded which makes them genetically more stable and the chances of them changing after injection are lower.
- Rabies vaccine is an adenovirus vaccine.
- Adenovirus vaccines are a type of viral vector vaccine.
- In this vaccine, adenovirus is used as a tool to deliver genes or vaccine antigens to the target host tissue.
- However, there are drawbacks of adenovirus vector vaccines like pre-existing immunity in humans, inflammatory responses etc.
- Just as human bodies develop immune responses to most real viral infections, they also develop immunity to adenoviral vectors. Since adenoviral vectors are based on natural viruses that some humans might already have been exposed to, these vaccines might not work for everyone.